John De Vos
LightNews LightNews
banner
jdevos.bsky.social
John De Vos
@jdevos.bsky.social
350 followers 380 following 240 posts

#StemCells Researcher | Director of the Cell Processing Facility
University of Montpellier - CHU of Montpellier | #StemCells #iPScells for #lung #CellTherapy |
Stem Genomics co-founder | President of the FSSCR

Videos
Biology 37%
Environmental science 10%
Posts Replies Media Videos

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 17h
😂

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 17h
I love this!
alexis-verger.cpesr.fr Alexis Verger 🧬🧫🧪 @alexis-verger.cpesr.fr · 2d
Let's try this #AcademicSky

1 fav, 1 funny, strange, or unexpected scientific anecdote about a paper, a scientist, a fact, hoping that some will be new to you.

Reposted by John De Vos

alexis-verger.cpesr.fr
Alexis Verger 🧬🧫🧪 @alexis-verger.cpesr.fr · 2d
Let's try this #AcademicSky

1 fav, 1 funny, strange, or unexpected scientific anecdote about a paper, a scientist, a fact, hoping that some will be new to you.

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos

norionakatsuji.bsky.social
Norio Nakatsuji @norionakatsuji.bsky.social · 11d
[AI companies will fail. We can salvage something from the wreckage | AI (artificial intelligence) |The Guardian]

“AI is asbestos in the walls of our tech society, stuffed there by monopolists run amok. A serious fight against it must strike at its roots“

www.theguardian.com/us-news/ng-i...
AI companies will fail. We can salvage something from the wreckage | Cory Doctorow
AI is asbestos in the walls of our tech society, stuffed there by monopolists run amok. A serious fight against it must strike at its roots
www.theguardian.com

Reposted by John De Vos

Reposted by John De Vos

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 15d
Another major triumph for a refractory autoimmune disease—hemolytic anemia—through engineered T cells
@nejm.org
nejm.org/doi/full/10....
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia | NEJM
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is d...
nejm.org

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos

stemcellreports.bsky.social
Stem Cell Reports @stemcellreports.bsky.social · 15d
Ludovic Vallier, Stem Cell Reports Associate Editor, is attending Biotherapy Days 2026 in Toulouse, France 28-30 January 2026. Connect with him to discuss whether your research is a fit for publishing in Stem Cell Reports!

Reposted by Stefan Rahmstorf, John De Vos, Du Toit , and 6 more

zacklabe.com
Zack Labe @zacklabe.com · 19d
2025 was the hottest year on record for ocean heat content. Unfortunately, we now say this every year. 🥹

"In addition to setting a new record in 2025, the global
ocean continues to show sustained and intensified warming."

+ #OpenAccess Study: doi.org/10.1007/s003...
+ Data: www.ocean.iap.ac.cn
Bar graph showing global ocean heat content change in the upper 2000 m from the late 1950s through 2025. There is a long-term warming in the time series, which is using IAP/CAS data.

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 21d
Other data regarding #CARTCell treatments in France. Interesting!

Source : buff.ly/k3Z9kDv

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 22d
Number of #CARTCell treatments in France : rapidly increasing.

Source : buff.ly/k3Z9kDv

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 22d
Solid tumor, allogeneic #CART alert 📣 : encouraging results from a phase I study using allogeneic IL-13Rα2 CAR-T cells in five people with recurrent high-grade glioma.

buff.ly/Q8RBlx4
News: Off-the-shelf CRISPR CAR-T tackles brain tumours - CRISPR Medicine
A first-in-human, phase I trial tested intrathecal delivery of CRISPR-Cas9-edited, allogeneic IL-13Rα2 CAR-T cells in five people with recurrent high-grade glioma. The single-centre study reports…
crisprmedicinenews.com

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 24d
Allogeneic #CARTCells in phase Ib/II clinical trials in China for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL). Phase I study showed interesting results.

buff.ly/SKuRXC9
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
SHANGHAI,Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted
news.futunn.com

Reposted by John De Vos

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 27d
"There’s a good likelihood that by 2050, all scientific research will be done
by superintelligent AI rather than human researchers,” Bostrom said in an e-mail. “Some humans might do science as a hobby, but they wouldn’t be making any useful contributions.”

The science of 2025

buff.ly/nElWVRL
Science in 2050: the future breakthroughs that will shape our world — and beyond
Nuclear fusion. People on Mars. Artificial general intelligence. These are just some of the advances that could come by the mid-century mark.
www.nature.com

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 27d
Monkey pluripotent stem cells-derived blastoids mature in vitro in 3D into Carnegie stage 8-9 (late gastrulation) embryos. Spectacular progress to study primate embryonic development.
buff.ly/IiFHeNU
Modelling late gastrulation in stem cell-derived monkey embryo models - Nature
An optimized 3D culture system enabled a stem cell-derived monkey blastoid to develop to day 25, recapitulating key events of primate late gastrula and demonstrating notable similarity to natural…
www.nature.com

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos